The PI3K/AKT pathway as a target for cancer treatment

Ingrid A. Mayer; Carlos L. Arteaga

doi:10.1146/annurev-med-062913-051343

The PI3K/AKT pathway as a target for cancer treatment

Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journal › Article › peer-review

539 Scopus citations

Abstract

Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.

Original language	English (US)
Pages (from-to)	11-28
Number of pages	18
Journal	Annual Review of Medicine
Volume	67
DOIs	https://doi.org/10.1146/annurev-med-062913-051343
State	Published - Jan 14 2016

Keywords

Breast cancer
Lymphoproliferative disorders
Mammalian target of rapamycin (mTOR)
Mutation
Pathway inhibitors
Phosphoinositide 3-kinase (PI3K)/AKT

ASJC Scopus subject areas

Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1146/annurev-med-062913-051343

Cite this

@article{71d6b155c55b4f62bba10e08648653aa,

title = "The PI3K/AKT pathway as a target for cancer treatment",

abstract = "Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.",

keywords = "Breast cancer, Lymphoproliferative disorders, Mammalian target of rapamycin (mTOR), Mutation, Pathway inhibitors, Phosphoinositide 3-kinase (PI3K)/AKT",

author = "Mayer, {Ingrid A.} and Arteaga, {Carlos L.}",

year = "2016",

month = jan,

day = "14",

doi = "10.1146/annurev-med-062913-051343",

language = "English (US)",

volume = "67",

pages = "11--28",

journal = "Annual Review of Medicine",

issn = "0066-4219",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - The PI3K/AKT pathway as a target for cancer treatment

AU - Mayer, Ingrid A.

AU - Arteaga, Carlos L.

PY - 2016/1/14

Y1 - 2016/1/14

N2 - Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.

AB - Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.

KW - Breast cancer

KW - Lymphoproliferative disorders

KW - Mammalian target of rapamycin (mTOR)

KW - Mutation

KW - Pathway inhibitors

KW - Phosphoinositide 3-kinase (PI3K)/AKT

UR - http://www.scopus.com/inward/record.url?scp=84954523816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954523816&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-062913-051343

DO - 10.1146/annurev-med-062913-051343

M3 - Article

C2 - 26473415

AN - SCOPUS:84954523816

SN - 0066-4219

VL - 67

SP - 11

EP - 28

JO - Annual Review of Medicine

JF - Annual Review of Medicine

ER -

The PI3K/AKT pathway as a target for cancer treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this